These four BofA Securities Growth 10 stocks come with reliable dividends and are are timely ideas for growth and income ...

He affirmed that the new drug "could take the epidemic to the history books," according to Mother Jones.Yeztugo, based on the ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

While Gilead Sciences’ HIV prevention drug lenacapavir got approved by the US FDA, its made-in-India generic versions may be ...

The U.S. Food and Drug Administration has approved a groundbreaking HIV prevention shot that only needs to be taken twice a year. Medical experts are calling it one of the most significant ...

The Food and Drug Administration has approved a new, first-of-its-kind semiannual HIV prevention medication, Gilead Sciences ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...

Clinical trials have shown that six-monthly injections of lenacapavir are almost 100 percent protective against becoming ...